117
Participants
Start Date
April 16, 2019
Primary Completion Date
December 13, 2022
Study Completion Date
April 21, 2023
Durvalumab
Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
Research Site, Guadalajara
Research Site, Milan
Research Site, Monza
Research Site, Großhansdorf
Research Site, Madrid
Research Site, Hanover
Research Site, Gainesville
Research Site, Toulouse
Research Site, Knoxville
Research Site, Seville
Research Site, Saint-Priest-en-Jarez
Research Site, Parma
Research Site, Valencia
Research Site, Meldola
Research Site, Hamm
Research Site, Heidelberg
Research Site, Paris
Research Site, Gauting
Research Site, Avellino
Research Site, Créteil
Research Site, Roma
Research Site, Barcelona
Research Site, Leeds
Research Site, Manchester
Research Site, Middlesbrough
Research Site, Nottingham
Research Site, Sheffield
Research Site, Stoke-on-Trent
Lead Sponsor
AstraZeneca
INDUSTRY